Purpose: Blocking the function of myeloid-derived Results: Patients with metastatic cancer had high blood suppressor cells (MDSC) is an attractive approach for levels of DC-HIL þ MDSCs compared with healthy controls. cancer immunotherapy. Having shown DC-HIL/GPNMB Anti-DC-HIL mAb reversed the in vitro function in 80% of to be the T-cell-inhibitory receptor mediating the sup-cancer patients tested, particularly for colon cancer. Despite pressor function of MDSCs, we evaluated the potential very low expression on blood MDSCs, anti-PDL1 mAb was as of anti-DC-HIL mAb as an MDSC-targeting cancer effective as anti-DC-HIL mAb in reversing MDSC function, a treatment. paradoxical phenomenon we found to be due to upregulated Experimental Design: Patients with metastatic cancer expression of PDL1 by T-cell-derived IFNg in cocultures. DC-(n ¼ 198) were analyzed by flow cytometry for DC-HIL or HIL is not expressed by colorectal cancer cells but by CD14 þ PDL1 expression on blood CD14 þ HLA-DR no/lo MDSCs. cells infiltrating the tumor. Finally, anti-DC-HIL mAb atten-Their suppressor function was assessed by in vitro co-uated growth of preestablished colon tumors by reducing culture with autologous T cells, and the ability of anti-MDSCs and increasing IFNg-secreting T cells in the tumor DC-HIL or anti-PDL1 mAb to reverse such function was microenvironment, with similar outcomes to anti-PDL1 mAb. determined. Tumor expression of these receptors was exam-Conclusions: Blocking DC-HIL function is a potentially use-ined histologically, and the antitumor activity of the mAb ful treatment for at least colorectal cancer with high blood levels was evaluated by attenuated growth of colon cancers in of DC-HIL þ MDSCs.
ASJC Scopus subject areas
- Cancer Research